Decabromodiphenyl ether causes insulin resistance and glucose and lipid metabolism disorders in mice

doi:10.4239/wjd.v12.i8.1267

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4438)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-10) series, Tables (1-5) series.

Item

Count

PDF

373

WORD

125

HTML

1991

Figures (1-10)

194

Tables (1-5)

399

Sum=3082

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

501

Download

855

Sum=1356

Aug 15, 2021 (publication date) through Aug 31, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Aug 15, 2021; 12(8): 1267-1281
Published online Aug 15, 2021. doi: 10.4239/wjd.v12.i8.1267

Table 1 Primer sequences for real-time quantitative polymerase chain reactions

Gene	Primer sequences (5'→3')	Length/bp
PPARγ	F-CTCCAAGAATACCAAAGTGCGA	104
	R-GCCTGATGCTTTATCCCCACA
Adiponectin	F-ATCTGGAGGTGGGAGACCAA	144
	R-GGGCATTGGGTAGTTGCAGT
β-actin	F-AGAGGGAAATCGTGCGTGACATCAAAGAG	196
	R-GATGCCACAGGATTCCATACCCAAGAAGG
Leptin	F: AGAGTGACAGGAAGTGCTGAGAGG	106
	R: TCTGACACCAGCCACCACGAG

Table 2 Comparisons of fasting blood glucose, homeostatic assessment model of insulin resistance, insulin sensitivity index, and insulin of mice in each group

Group	FINS (mIU/L)	ISI	HOMA-IR	FBG
High dose	20.91 ± 0.96^a^,^b^,^c	0.78 ± 0.13^a^,^b^,^c	8.38 ± 0.44^a	8.85 ± 0.35^a^,^b^,^c
Medium-high dose	21.71 ± 0.56^a^,^b^,^c	0.94 ± 0.11^a^,^b^,^c	8.28 ± 0.37^a	8.58 ± 0.32^a^,^b^,^c
Medium dose	23.87 ± 0.46^a^,^c	1.05 ± 0.32^a^,^c	8.15 ± 0.43^a	7.81 ± 0.49^a
Medium-low dose	24.89 ± 0.27^a^,^c	1.08 ± 0.11^a^,^c	7.76 ± 0.53	7.02 ± 0.44
Low dose	26.02 ± 0.84^a	1.41 ± 0.21	7.56 ± 0.61	6.53 ± 0.39
Control	27.37 ± 0.28	1.57 ± 0.08	7.57 ± 0.65	6.52 ± 0.68
F value	61.06	2.968	2.719	28.574
P value	0.001	0.027	0.038	0.001

^aP < 0.05 compared with the control group.

^bP < 0.05 compared with the medium dose group.

^cP < 0.05 compared with the low dose group. FINS: Fasting insulin; ISI: Insulin sensitivity index; HOMA-IR: Homeostatic assessment model of insulin resistance; FBG: Fasting blood glucose.

Table 3 Comparisons of blood lipid indexes in mice of each group (mmoL/L)

Group	TC	TG	LDL-C	HDL-C
High dose	5.29 ± 1.20^a^,^b^,^c	1.46 ± 0.36^a^,^b^,^c	2.44 ± 0.21^a^,^b^,^c	1.33 ± 0.12^a^,^b^,^c
Medium-high dose	4.64 ± 0.49^a	1.12 ± 0.11^a	2.14 ± 0.29^a^,^c	1.51 ± 0.12^a^,^c
Medium dose	3.67 ± 0.49^a	0.97 ± 0.14^a	1.95 ± 0.49^a^,^c	1.53 ± 0.17^a
Medium-low dose	3.48 ± 0.64^a	0.92 ± 0.18^a	1.78 ± 0.34^a	1.72 ± 0.10^a
Low dose	3.36 ± 1.11^a	0.91 ± 0.06^a	1.70 ± 0.15^a	1.73 ± 0.10^a
Control	2.95 ± 1.35	0.75 ± 0.07	1.27 ± 0.15	1.95 ± 0.10
F value	5.38	10.32	13.3	17.44
P value	0.002	0.001	0.001	0.001

TC: Total cholesterol; TG: Tri-glyceride; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol.

^aP < 0.05 compared with the control group.

^bP < 0.05 compared with the medium dose group.

^cP < 0.05 compared with the low dose group.

Table 4 Comparison of relative expression levels of adiponectin, leptin, and peroxisome proliferators activated receptor-γ genes in liver tissue of mice in each group (X ± S, 2^-ΔΔCt)

Group	n	*Adp*	*LEP*	*PPARγ*
High dose	6	1.85 ± 0.25^a^,^c	3.27 ± 0.80^a^,^b^,^c	2.96 ± 0.98^a
Medium-high dose	6	2.25 ± 0.37^a^,^c	2.61 ± 0.62^a^,^b^,^c	2.93 ± 0.95^a
Medium dose	6	2.63 ± 0.41^a	1.58 ± 0.48	2.56 ± 1.18^a
Medium-low dose	6	3.24 ± 0.99^a	1.47 ± 0.59	1.68 ± 0.71
Low dose	6	3.38 ± 0.89^a	1.09 ± 0.57	1.71 ± 0.24
Control	6	1.00 ± 0.00	1.00 ± 0.00	1.00 ± 0.00
F value		13.38	15.16	5.61
P value		0.001	0.001	0.001

^aP < 0.05 compared with the control group.

^bP < 0.05 compared with the medium dose group.

^cP < 0.05 compared with the low dose group. Adp: Adiponectin; LEP: leptin; PPARγ: Peroxisome proliferators activated receptor-γ.

Table 5 Comparison of relative expression levels of adiponectin, leptin, and proliferators activated receptor-γ genes in adipose tissue of mice in each group (X ± S, 2^-ΔΔCt)

Group	n	*Adp*	*LEP*	*PPARγ*
High dose	6	0.97 ± 0.16^b^,^c	3.12 ± 1.86^a^,^b^,^c	1.39 ± 0.31^a^,^c
Medium-high dose	6	1.27 ± 0.34^c	2.35 ± 1.08^a^,^c	1.35 ± 0.21^a^,^c
Medium dose	6	1.24 ± 0.32^c	1.59 ± 1.19	1.17 ± 0.34^a^,^c
Medium-low dose	6	1.52 ± 0.54^a	1.35 ± 0.76	0.90 ± 0.20
Low dose	6	1.61 ± 0.43^a	1.32 ± 0.46	0.72 ± 0.10
Control	6	1.00 ± 0.00	1.00 ± 0.00	1.00 ± 0.20
F value		3.36	3.35	7.85
P value		0.016	0.016	0.001

^aP < 0.05 compared with the control group.

^bP < 0.05 compared with the medium dose group.

^cP < 0.05 compared with the low dose group. Adp: Adiponectin; LEP: Leptin; PPARγ: Peroxisome proliferators activated receptor-γ.

Citation: Alimu A, Abudureman H, Wang YZ, Li MY, Wang JS, Liu ZL. Decabromodiphenyl ether causes insulin resistance and glucose and lipid metabolism disorders in mice. World J Diabetes 2021; 12(8): 1267-1281
URL: https://www.wjgnet.com/1948-9358/full/v12/i8/1267.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i8.1267